Fulcrum Therapeutics, Inc.’s Free Cash Flow Growth at a glance
Fulcrum Therapeutics, Inc. reports free cash flow growth of 97.3% for Dec 2024. The prior period recorded 7.6% (Dec 2023). Year over year the metric moved +89.7 pts (+1,177.3%). The rolling three-period average stands at 27.1%. Data last refreshed Dec 7, 2025, 2:50 AM.
Latest reading
97.3% · Dec 2024
YoY movement
+89.7 pts (+1,177.3%)
Rolling average
27.1%
Current Free Cash Flow Growth
97.3%
+89.7 pts
+1,177.3%
Rolling average
27.1%
Latest Value
97.3%
Dec 2024
YoY Change
+89.7 pts
Absolute
YoY Change %
+1,177.3%
Rate of change
3-Period Avg
27.1%
Smoothed
Narrative signal
Fulcrum Therapeutics, Inc.’s free cash flow growth stands at 97.3% for Dec 2024. Year-over-year, the metric shifted by +89.7 pts, translating into a +1,177.3% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How free cash flow growth shapes Fulcrum Therapeutics, Inc.'s story
As of Dec 2024, Fulcrum Therapeutics, Inc. reports free cash flow growth of 97.3%. Gauge reinvestment strength and capital return capacity using free cash flow growth over multiple reporting periods.
Cash flow versus earnings
Free cash flow growth can diverge from earnings due to working capital and capex swings. Track both to confirm quality.
Capital allocation insights
Rising free cash flow enables dividends, buybacks, and debt reduction—key levers for shareholder value.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
98%
Operating Margin
-27.4%
Net Profit Margin
-12.2%
Return on Equity
-4%
Return on Assets
-3.7%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Fulcrum Therapeutics, Inc. (FULC) FAQs
Answers tailored to Fulcrum Therapeutics, Inc.’s free cash flow growth profile using the latest Financial Modeling Prep data.
What is Fulcrum Therapeutics, Inc.'s current free cash flow growth?
As of Dec 2024, Fulcrum Therapeutics, Inc. reports free cash flow growth of 97.3%. This reading reflects the latest filings and price data for FULC.
How is Fulcrum Therapeutics, Inc.'s free cash flow growth trending year over year?
Year-over-year, the figure shifts by +89.7 pts (+1,177.3%). Pair this context with revenue growth and free cash flow signals to gauge momentum for FULC.
Why does free cash flow growth matter for Fulcrum Therapeutics, Inc.?
Free cash flow growth measures how quickly operating cash surplus expands compared with the prior period. For Fulcrum Therapeutics, Inc., operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Fulcrum Therapeutics, Inc.'s free cash flow growth above its recent average?
Fulcrum Therapeutics, Inc.'s rolling three-period average sits at 27.1%. Comparing the latest reading of 97.3% to that baseline highlights whether momentum is building or fading for FULC.
How frequently is Fulcrum Therapeutics, Inc.'s free cash flow growth refreshed?
Data for FULC was last refreshed on Dec 7, 2025, 2:50 AM and updates automatically every 24 hours, keeping your valuation inputs current.